ABSTRACT
either COBI or RTV for three days, followed by co-incubation with DRV for one hour.
23
Resultant DRV concentrations were quantified by HPLC-UV, and the apparent intrinsic 
30
Incubation of either RTV, or COBI, in combination with RIF was sufficient to overcome induced elevations in DRV CL int.app. , with RTV more potent than COBI. These data provide the 32 first in vitro experimental insight into DDIs between RIF and COBI-boosted or RTV-boosted 33 DRV, and will be useful to inform physiologically-based pharmacokinetic models to aid in phase I metabolism by cytochrome p450 3A4 (CYP3A4), and are also substrates of P-43 glycoprotein (P-gp; ABCB1) (6). Consequently, PIs are commonly administered in combination 44 with pharmacokinetic (PK) "boosters" such as ritonavir (RTV) or cobicistat (COBI), which act 45 by inhibiting CYP3A4-mediated PI metabolism and P-gp-mediated PI efflux, thereby improving 46 the PK profile of PIs by prolonging PI half-life, and increasing PI bioavailability (7-9).
48
Rifampicin (RIF) is an essential component of short-course anti-TB treatment regimens 49 (2, 10); however, RIF is also a potent inducer of the expression and activity of several metabolic 50 enzymes -including CYP3A4 (11). Co-administering RIF with PIs can result in clinically-51 significant drug-drug interactions (DDIs), whereby PI bioavailability may be significantly 52 reduced (>75%) (10, (12) (13) (14) 
124
Standards and quality control samples were prepared in WME incubation medium and were 125 treated in the same way. All samples were then vortexed for five seconds, and were dried in a 
136
C/30% D from 9.5 to 12.5 min. Elution was carried out at room temperature (18-25°C), and 137 the flow rate was maintained at 1.00 ml/min. Chromatograms were analysed and DRV was 138 quantified at 267 nm using Chromeleon software (version 6.8; Thermo Fisher Ltd. at each concentration of RIF tested (0.5-20 µM) (Fig. 1) . The 169 maximal RIF-induced increase (1.9 ± 0.3-fold; n=3) in DRV CL int.app. was observed with 10 µM 170 RIF (Fig. 1) .
171
Co-incubation of RIF with RTV reduced 10 μM RIF-induced increases in CL int.app. in a
172
RTV concentration-dependent manner (Fig. 1) . Notably, RTV (1 μM) was sufficient to 173 overcome the effect of 10 μM RIF on DRV CL int.app. , reducing DRV CL int.app. to 0.78 ± 0.25-fold
174
-equivalent to -22% when compared to control levels in which cells were treated with DRV 175 alone (n=3; Fig. 1 ). Increasing RIF concentrations above 10 µM (12.5-20 μM) did not impact 176 the effectiveness of RTV to overcome RIF-elevated DRV CL int.app. (Fig. 1) COBI being sufficient to lower DRV CL int.app to 11.6 ± 2.6 μl/min/10 6 hepatocytes (n=3), 13%
193 below DRV control levels (Fig. 2) treated with 10 µM RIF alone (Fig. 3) . The effective concentration 50% of maximum response
203
(EC 50 ) of COBI and RTV calculated from the percentage-change in DRV CL int.app. under these 204 conditions was 1.5 µM for COBI and 2.6 µM for RTV (Fig. 3) (Fig. 1 and Fig. 2) . This is likely due to induction of CYP3A4 (17, physiologically-based PK (PBPK) modelling-based study that investigated the PK of DRV/r 246 during pregnancy has also suggested a role for hepatic transporters in DRV disposition (40).
247
Co-incubation of human cryopreserved hepatocytes with COBI and RIF, or RTV and RIF
248
-using concentrations spanning the in vivo therapeutic range of these compounds -revealed that 249 both RTV and COBI could reduce RIF-enhanced DRV CL int.app. in a concentration-dependent 250 manner ( Fig. 1 and Fig. 2) . RTV was more effective than COBI at attenuating the RIF-induced 251 increase in DRV CL int.app. , with RTV exhibiting a lower EC 50 compared to COBI, whilst RTV 252 also achieved greater maximal inhibition of the 10 µM RIF-induced increase in DRV CL int.app.
253
compared to COBI (Fig. 3) . Furthermore, regression analysis revealed a stronger effect of RTV although it has been suggested that the induction potential of COBI is less than that of RTV (45) 
270
In addition, chronic exposure to RIF has been shown to exert an inhibitory effect on P-gp in vitro 271 (49). It remains to be seen therefore what the net contribution of transporters such as OATP1B1,
272
OATB1B3 and P-gp may be on plasma levels of DRV in vivo, especially when DRV is 273 administered in combination with other compounds such as RIF.
274
The PK profiles of DRV/r (800/100 mg, qd) and DRV/c (800/150 mg, qd) in HIV- showed that TPV AUC, C max and C tau levels were significantly lower with COBI compared to 280 RTV (53). Collectively, these studies suggest that the pharmacoenhancment with COBI is not 281 always equal to that of RTV. showed that administering ATV/RTV 300/100 mg, ATV/RTV 300/200 mg, and ATV/RTV 297 400/200 mg was insufficient to completely overcome the inductive potential of RIF 600 mg (12).
298
In an effort to better understand the absorption, distribution, metabolism and elimination of 299 various compounds, the use of PBPK models has recently gained popularity (56 
